1. Home
  2. Approved trials
  3. » فارسی

In- Vivo Bioequivalence study of Eplerenone tablet 50mg Anourayhan (Alderon 50mg) with brand drugs (Inspra 50mg, Pfizer, Gremany) in Iranian healthy volunteers

Protocol summary

Study aim
In- Vivo Bioequivalence study of Eplerenone tablet 50mg Abourayhan (Alderon 50mg) with brand drugs (Inspra 50mg, Pfizer, Gremany).
Design
Single dose, randomized, two sequences, two period crossover with a washout period.
Settings and conduct
This study will be conducted in two-way, cross-over and fasting, and on two sets of healthy volunteers. The study will be conducted in two periods of twenty-four hours.The interval between these two periods, which is called the wash-out time, is determined by the half-life of the drug plasma, which according to scientific sources should be at least 5 to 7 half-life of the drug in the case of the drug under study. The plan will take a week to clean up the drug, given the biological half-life of the drugs in the drug form.In the first round, candidates are divided into two groups, and the first group receives a test tablet and the second group receives a similar tablet. Blood samples will taken by the volunteer by the technician immediately after taking the drug, and the preparation steps of the samples, including plasma separation and drug extraction, are performed to analyze the amount of drug on them.
Participants/Inclusion and exclusion criteria
24 participants will be selected from non-smoking, not pregnant people with no history of heart, kidney and liver disease or dis functions with both sex (male&female). The ages and BMIs of participant should be in the range of 18-60 and 18-25 respectively.
Intervention groups
Both groups received in cross-over design medication and testing at two different cross-sections and Therefor,the test results are independent of individual differences and it will only show the difference in the formulation of the two drugs.
Main outcome variables
Cmax,Tmax, T1/2, Ke (Elemination)

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20200105046010N2
Registration date: 2020-06-09, 1399/03/20
Registration timing: registered_while_recruiting

Last update: 2020-06-09, 1399/03/20
Update count: 0
Registration date
2020-06-09, 1399/03/20
Registrant information
Name
Javad Shokri
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3661 4125
Email address
shokri.j@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-05-25, 1399/03/05
Expected recruitment end date
2020-11-25, 1399/09/05
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
In- Vivo Bioequivalence study of Eplerenone tablet 50mg Anourayhan (Alderon 50mg) with brand drugs (Inspra 50mg, Pfizer, Gremany) in Iranian healthy volunteers
Public title
Eplerenone tablet 50mg Abourayhan (Alderon 50mg),In-Vivo Bioequivalence in iranian healthy volunteer
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
General health(liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)
Exclusion criteria:
Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug
Age
From 18 years old to 60 years old
Gender
Both
Phase
Bioequivalence
Groups that have been masked
  • Participant
Sample size
Target sample size: 24
Randomization (investigator's opinion)
Randomized
Randomization description
People in different age groups are invited to cooperate through the advertisement.Then people are selected. Individuals will be randomly selected through advertisements. The number of individuals will be randomly selected and the first twelve will be selected as the first sequence and the second twelve will be selected as the second sequence.
Blinding (investigator's opinion)
Single blinded
Blinding description
Candidates are not aware of the test drug or brand name.
Placebo
Not used
Assignment
Crossover
Other design features
Tow period / Tow sequence with a washout time

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Tabriz University of Medical Sciences Ethics Committee
Street address
No.48,Ferdows street, Ferdowsi Sq.
City
Tabriz
Province
East Azarbaijan
Postal code
51678744
Approval date
2019-12-23, 1398/10/02
Ethics committee reference number
IR.TBZMED.REC.1398.1044

Health conditions studied

1

Description of health condition studied
In this study the bioequivalence of test and brand of Esmoprazole will evaluated.
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Drug analysis in plasma or whole blood
Timepoint
After blood sampling
Method of measurement
HPLC,LC-MS/MS or UPLC-MS/MS

Secondary outcomes

empty

Intervention groups

1

Description
Single dose of Eplerenone 50 mg tablet by (INSPRA® 50mg. Pfizer, Germany)Pharmaceutical Company as a reference product.
Category
Treatment - Drugs

2

Description
Single dose of 50 mg Eplerenone tablet by Abu Reihan Pharmaceutical Company as a test product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Simin Baspar Teyf Gostar Company
Full name of responsible person
Javad Shokri
Street address
No.48,Ferdos Street
City
Tabriz
Province
East Azarbaijan
Postal code
5167874434
Phone
+98 41 3384 2724
Email
Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Aburayhan Pharmaceutical Co.
Full name of responsible person
Cobra moosavi, Pharm D.
Street address
Tehranpars intersection, Khoshvaght St. No. 1, Po.Box 16765/1568, Postal Cod: 1654613111
City
Tehran
Province
Tehran
Postal code
1654613111
Phone
+98 21 7770 7173
Fax
+98 21 7770 2066
Email
info@aburaihan.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Aburayhan Pharmaceutical Co.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Tabriz University of Medical Sciences, Faculty of Pharmacy
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
shokri.j@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Tabriz University of Medical Sciences
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
shokri.j@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Tabriz University faculty of pharmacy
City
Tabriz
Province
East Azarbaijan
Postal code
5166414766
Phone
+98 41 3334 8489
Email
shokri.j@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
These date are as secure between researcher and related industries.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Only protocol and methods of study are sharable.
When the data will become available and for how long
After finishing of the protocol (Probably 6 months receiving IRCT code)
To whom data/document is available
Pharmaceutical and medical sciences researchers.
Under which criteria data/document could be used
Projects information's for any publications is not allowed.
From where data/document is obtainable
Contact with E-mail of the main researcher.
What processes are involved for a request to access data/document
Personal and academic details and the aim of the request.
Comments
Loading...